Barakat R, Chatterjee J, Mu R, Qi X, Gu X, Smirnov I
Nat Commun. 2024; 15(1):10312.
PMID: 39609412
PMC: 11605098.
DOI: 10.1038/s41467-024-54569-4.
Chan A, Zhang K, Martin G, Bano S, Chatterjee J, Mahto S
Neuro Oncol. 2024; 26(12):2339-2351.
PMID: 39023130
PMC: 11630557.
DOI: 10.1093/neuonc/noae136.
Chen Y, Yu J, Ge S, Jia R, Song X, Wang Y
Invest Ophthalmol Vis Sci. 2024; 65(6):8.
PMID: 38837168
PMC: 11160950.
DOI: 10.1167/iovs.65.6.8.
Pan Y, Hysinger J, Yalcin B, Lennon J, Byun Y, Raghavan P
Nat Neurosci. 2024; 27(8):1555-1564.
PMID: 38816530
PMC: 11303248.
DOI: 10.1038/s41593-024-01654-y.
Miyagishima K, Qiao F, Stasheff S, Nadal-Nicolas F
Vision (Basel). 2024; 8(2).
PMID: 38804352
PMC: 11130890.
DOI: 10.3390/vision8020031.
MOST wanted: navigating the MAPK-OIS-SASP-tumor microenvironment axis in primary pediatric low-grade glioma and preclinical models.
Sigaud R, Brummer T, Kocher D, Milde T, Selt F
Childs Nerv Syst. 2024; 40(10):3209-3221.
PMID: 38789691
PMC: 11511703.
DOI: 10.1007/s00381-024-06463-z.
NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma.
Anastasaki C, Chatterjee J, Koleske J, Gao Y, Bozeman S, Kernan C
Neuro Oncol. 2024; 26(8):1496-1508.
PMID: 38607967
PMC: 11300021.
DOI: 10.1093/neuonc/noae054.
The +/- Immune Microenvironment: Dueling Roles in Neurofibroma Development and Malignant Transformation.
White E, Rhodes S
Cancers (Basel). 2024; 16(5).
PMID: 38473354
PMC: 10930863.
DOI: 10.3390/cancers16050994.
Pediatric low-grade glioma models: advances and ongoing challenges.
Yvone G, Breunig J
Front Oncol. 2024; 13:1346949.
PMID: 38318325
PMC: 10839015.
DOI: 10.3389/fonc.2023.1346949.
Brain injury drives optic glioma formation through neuron-glia signaling.
Chatterjee J, Koleske J, Chao A, Sauerbeck A, Chen J, Qi X
Acta Neuropathol Commun. 2024; 12(1):21.
PMID: 38308315
PMC: 10837936.
DOI: 10.1186/s40478-024-01735-w.
Estrogen-induced glial IL-1β mediates extrinsic retinal ganglion cell vulnerability in murine Nf1 optic glioma.
Tang Y, Chatterjee J, Wagoner N, Bozeman S, Gutmann D
Ann Clin Transl Neurol. 2024; 11(3):812-818.
PMID: 38229454
PMC: 10963305.
DOI: 10.1002/acn3.51995.
The Neuroimmune Regulation and Potential Therapeutic Strategies of Optic Pathway Glioma.
Irshad K, Huang Y, Rodriguez P, Lo J, Aghoghovwia B, Pan Y
Brain Sci. 2023; 13(10).
PMID: 37891793
PMC: 10605541.
DOI: 10.3390/brainsci13101424.
Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.
Milde T, Fangusaro J, Fisher M, Hawkins C, Rodriguez F, Tabori U
Neuro Oncol. 2023; 25(11):1920-1931.
PMID: 37738646
PMC: 10628935.
DOI: 10.1093/neuonc/noad125.
Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects.
Tang Y, Gutmann D
Cancer Manag Res. 2023; 15:667-681.
PMID: 37465080
PMC: 10351533.
DOI: 10.2147/CMAR.S362678.
Clinical signs and genetic evaluation of patients with neurofibromatosis type 1 with and without optic pathway gliomas in a center in Turkey.
Sharafi P, Varan A, Ersoy-Evans S, Ayter S
Childs Nerv Syst. 2023; 40(2):511-515.
PMID: 37401974
DOI: 10.1007/s00381-023-06061-5.
A new era for myelin research in Neurofibromatosis type 1.
de Blank P, Nishiyama A, Lopez-Juarez A
Glia. 2023; 71(12):2701-2719.
PMID: 37382486
PMC: 10592420.
DOI: 10.1002/glia.24432.
RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
Rhodes S, McCormick F, Cagan R, Bakker A, Staedtke V, Ly I
J Invest Dermatol. 2023; 143(8):1358-1368.
PMID: 37245145
PMC: 10409534.
DOI: 10.1016/j.jid.2023.01.043.
Establishing Brain Tumor Stem Cell Culture from Patient Brain Tumors and Imaging Analysis of Patient-Derived Xenografts.
Mahmoudian E, Jahani-Asl A
Methods Mol Biol. 2023; 2736:177-192.
PMID: 37243860
DOI: 10.1007/7651_2023_482.
Human induced pluripotent stem cell engineering establishes a humanized mouse platform for pediatric low-grade glioma modeling.
Anastasaki C, Chatterjee J, Cobb O, Sanapala S, Scheaffer S, Costa A
Acta Neuropathol Commun. 2022; 10(1):120.
PMID: 35986378
PMC: 9392324.
DOI: 10.1186/s40478-022-01428-2.
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.
Lucas C, Sloan E, Gupta R, Wu J, Pratt D, Vasudevan H
Acta Neuropathol. 2022; 144(4):747-765.
PMID: 35945463
PMC: 9468105.
DOI: 10.1007/s00401-022-02478-5.